Mumbai, Aug 14 (IANS) Alkem Laboratories on Friday reported a 21.7 per cent year-on-year (YoY) decline in consolidated net profit for the first quarter of current financial year (Q1 FY27).
The drugmaker posted a net profit of Rs 520 crore in Q1 FY27, compared with Rs 664 crore in the corresponding quarter of the previous financial year (Q1 FY26), according to its stock exchange filing.
Revenue from operations rose 10.9 per cent year-on-year to Rs 3,740 crore from Rs 3,371 crore a year earlier.
Growth was driven by both domestic and international businesses. India sales increased 10.3 per cent to Rs 2,497.8 crore, while international sales climbed 16 per cent to Rs 1,222.3 crore.
At the operating level, Alkem reported healthy performance during the quarter. EBITDA rose 16.2 per cent year-on-year to Rs 766.6 crore from Rs 660 crore in the year-ago period.
EBITDA margin improved to 20.5 per cent from 19.6 per cent, as per its regulatory filing.
However, the company’s tax expense surged to Rs 251 crore during the quarter, compared with Rs 103 crore in the corresponding period last financial year, weighing on bottom-line growth.
Commenting on the results, Managing Director Sandeep Singh said Alkem had begun FY27 on a steady note, supported by healthy growth in both its India and international businesses.
“We have started FY27 on a steady note, with healthy growth across our India and international businesses. Our India business continued to outperform the market, while the strong growth in our non-US international markets was encouraging,” he said.
“At the same time, there are areas where we need to improve, particularly in strengthening execution, addressing operational and regulatory priorities, and improving the consistency of performance across our businesses,” Singh added.
We are also investing in R&D, MedTech and Biotech as we build our next phase of growth. Our focus will be to strengthen the core, address the areas that need improvement and build these newer opportunities in a disciplined manner, he mentioned further.
–IANS
pk
